Multi-centre trials: U-turns by bandwagons and the patient left by the wayside

British Journal of Clinical Pharmacology

Volumn 42, Issue 2, 1996, Pages 143-145

  Dobbs, S M ^a   Dobbs, R J ^a   Charlett, A ^b  

^a HILLINGDON HOSPITAL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; SELEGILINE;

CLINICAL PHARMACOLOGY; CLINICAL TRIAL; DRUG SAFETY; EDITORIAL; HUMAN; MULTICENTER STUDY; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0030016855     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.d01-3294.x     Document Type: Editorial

References (33)

1. Laurence DR. Clinical pharmacology. Fourth Edition. Churchill Livingstone, London 1973: 4.11.
2. Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B. Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn 1965; 155: 154-64.
3. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP Parkinsonism J Neurosci Res 1991; 30: 666-672.
4. Salo PT, Tatton WG. Deprenyl reduces the death of motorneurones caused by axotomy. J Neurosci Res 1992; 31: 394-400.
5. Tariot PN, Cohen RM, Sunderland T, et al. L-Deprenyl in Alzheimer's disease. Arch Gen Psychiat 1987; 44: 427-433.
6. Mangoni A, Grassi MP, Frattola L, et al. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur Neurol 1991; 31: 100-107.
7. Brandeis R, Sapir M, Kapon Y, Borelli G, Cadel S, Valsecchi B. Improvement of cognitive function by MAO-B inhibitor L-deprenyl in aged rats. Pharmacol Biochem Behav 1991; 39: 297-304.
8. Calne D, Eisen A. Parkinson's disease, motorneuron disease and Alzheimer's disease: origins and interrelationship. In Advances in Neurology. Vol 53. Parkinson's disease: anatomy, pathology and therapy, eds Streifler MB, Korczyn AD, Melamed E, Youdim MBH. New York: Raven Press, 1990.
9. Calne DB, Eisen A, McGeer E, Spencer P. Alzheimer's disease, Parkinson's disease, and motoneurone disease, abiotrophic interaction between ageing and environment. Lancet 1986; ii: 1067-1070.
10. Knoll J, Dallo J, Yen TT. Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl. Life Sci 1989; 45: 525-531.
11. Birkmeyer W, Knoll J, Riederer P, Youdim MBH, Hars V, Matron J. Increased life expectancy resulting from addition of L-deprenyl to Madopar R treatment in Parkinson's disease: a long term study. J Neural Transm 1985; 64: 113-127.
12. Csanda E, Tárczy M. Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease. Acta Neurol Scand 1983; (Suppl 95): 117-122.
13. Tetrud JW Langston W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245: 519-522.
14. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364-1371.
15. Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Selegiline as a primary treatment of Parkinson's disease. Acta Neurol Scand 1991; 84 (Suppl 136): 70-72.
16. Allain H, Cougnard J, Neukirch H-C, the FSMT members. Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMT). Acta Neurol Scand 1991; 84 (Suppl 136): 73-78.
17. The Parkinson Study Group. Effects of Tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328: 176-83.
18. Golbe LI. Deprenyl as symptomatic therapy in Parkinson's disease. Clin Neuropharmacol 1988; 11: 387-400.
19. Heinonen EH, Rinne UK. Selegiline in the treatment of Parkinson's disease. Acta Neurol Scand 1989; 80 (Suppl 126): 103-111.
20. Eisler T, Teräväinen H, Nelson R, et al. Deprenyl in Parkinson disease. Neurology 1981; 31: 19-23.
21. The Parkinson Study Group. Effect of deprenyl on neuropsychological function in early Parkinson's disease. Ann Neurol 1990; 28: 297.
22. Kirollos C, Charlett, A, Bowes SG, et al. Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinsonism. Eur J Clin Pharmacol 1996; 49: 7-18.
23. Sonsalla PK, Golbe LI. Deprenyl as prophylaxis against Parkinson's disease? Clin Neuropharmacol 1988; 11: 500-511.
24. Heinonen EH, Lammintansta R. A review of the pharmacology of selegiline. Acta Neurol Scand 1991; 84 (Suppl 136): 44-59.
25. Mäki-ikola O, Heinonen E, Helajdrvi H. Safety report on selegiline and mortality. Orion-Farmos, Helsinki 1995: 1-27.
26. Mäki-ikola O, Kilkku O, Heinonen E. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Other studies have not shown increased mortality. Br Med J 1996; 312: 702.
27. Calne DB. Selegiline in Parkinson's disease. Br Med J 1995; 311: 1583-1584.
28. Lees A J on behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br Med J 1995; 311: 1602-1607.
29. Lees AJ, Head J, Ben-Shlomo Y. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Authors' reply. Br Med J 1996; 312: 704-705.
30. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Br Med J 1996; 312: 702-705.
31. British National Formulary. British Medical Association and the Royal Pharmaceutical Society of Great Britain, London 1984: 181.
32. Bowes SG, Dobbs RJ, Henley, M, et al. Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/ carbidopa. Eur J Clin Pharmacol 1992; 43: 483-489.
33. Olanow CW, Godbold JH, Koller W. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Patients taking selegiline may have received more levodopa than necessary. Br Med J 1996; 312: 702-703.